Although current everolimus-eluting coronary stents have shown improved event-free
survival within the first year following implantation compared with bare-metal stents or earlier …

The permanent metal prosthesis common to bare metal stents (BMS) as well as both first‐
and second‐generation drug‐eluting stents (DES) following treatment of coronary artery …

Contemporary metallic drug-eluting stents are associated with very good 1-year outcomes
but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction …

Background Compared with metallic drug-eluting stents, bioresorbable vascular scaffolds
(BVS) offer the potential to improve long-term outcomes of percutaneous coronary …

Background In the last years bioresorbable vascular scaffold (BVS) become a new
therapeutic option for interventional cardiologists, with the advantage of a scaffold inducing …

Background Randomized trials have demonstrated progressive improvements in clinical
and angiographic measures of restenosis with technologic iterations from balloon …

Background In patients with coronary artery disease who receive metallic drug-eluting
coronary stents, adverse events such as late target-lesion failure may be related in part to …

Abstract Purpose of Review The purpose of this review is to present an overview of the
recent evidence regarding the use of bioresorbable scaffolds in percutaneous coronary …

Abstract Background: The Absorb everolimus-eluting poly-L-lactic acid–based
bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support …

Background: The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3
years after coronary artery implantation. The safety and effectiveness of BVS through this …